-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Amylyx Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q3 2025.
- Amylyx Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $0.000.
- Amylyx Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was -$635K, a 132% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2024 was -$393K, a 108% decline from 2023.
- Amylyx Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $5.03M, a 549% increase from 2022.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)